Cellectar Biosciences, Inc.
CLRB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 0.02 | -0.00 |
| FCF Yield | -44.72% | -64.58% | -79.65% | -10.89% |
| EV / EBITDA | -0.14 | -0.17 | 0.71 | -3.80 |
| Quality | ||||
| ROIC | -76.23% | -63.31% | -81.09% | -78.12% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.96 | 0.94 | 1.42 | 4.63 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 45.48% | 14.50% | -19.72% | 35.27% |
| Safety | ||||
| Net Debt / EBITDA | 1.77 | 2.12 | 1.80 | 2.55 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |